GR3031896T3 - Stable liquid composition containing urate oxidase and lyophilized composition for its preparation - Google Patents

Stable liquid composition containing urate oxidase and lyophilized composition for its preparation

Info

Publication number
GR3031896T3
GR3031896T3 GR990402988T GR990402988T GR3031896T3 GR 3031896 T3 GR3031896 T3 GR 3031896T3 GR 990402988 T GR990402988 T GR 990402988T GR 990402988 T GR990402988 T GR 990402988T GR 3031896 T3 GR3031896 T3 GR 3031896T3
Authority
GR
Greece
Prior art keywords
urate oxidase
preparation
stable liquid
composition containing
liquid composition
Prior art date
Application number
GR990402988T
Other languages
English (en)
Inventor
Claude Aleman
Alain Bayol
Thierry Breul
Patrice Dupin
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of GR3031896T3 publication Critical patent/GR3031896T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • A61K38/443Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GR990402988T 1995-05-11 1999-11-18 Stable liquid composition containing urate oxidase and lyophilized composition for its preparation GR3031896T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9505606A FR2733914B1 (fr) 1995-05-11 1995-05-11 Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US08/644,163 US5811096A (en) 1995-05-11 1996-05-10 Stable liquid composition containing urate oxidase and lyophilized composition for its preparation

Publications (1)

Publication Number Publication Date
GR3031896T3 true GR3031896T3 (en) 2000-02-29

Family

ID=26231954

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990402988T GR3031896T3 (en) 1995-05-11 1999-11-18 Stable liquid composition containing urate oxidase and lyophilized composition for its preparation

Country Status (24)

Country Link
US (1) US5811096A (el)
EP (1) EP0742013B1 (el)
JP (1) JP2950775B2 (el)
CN (1) CN1090972C (el)
AT (1) ATE183925T1 (el)
AU (1) AU710288B2 (el)
BR (1) BR1100337A (el)
CA (1) CA2175971C (el)
CZ (1) CZ290799B6 (el)
DE (1) DE69604009T2 (el)
DK (1) DK0742013T3 (el)
EA (1) EA000024B1 (el)
ES (1) ES2137635T3 (el)
FR (1) FR2733914B1 (el)
GR (1) GR3031896T3 (el)
HU (1) HU225147B1 (el)
IL (1) IL118171A (el)
NO (1) NO315261B1 (el)
NZ (1) NZ286554A (el)
PL (1) PL184135B1 (el)
SG (1) SG42355A1 (el)
SI (1) SI0742013T1 (el)
TW (1) TW420614B (el)
ZA (1) ZA963683B (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CN1896231B (zh) * 1998-08-06 2012-09-05 山景药品公司 分离四聚体尿酸氧化酶的方法
FR2782455B3 (fr) * 1998-08-20 2000-09-15 Sanofi Sa Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine
EP1598074B1 (en) * 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
JP4699991B2 (ja) * 2003-04-02 2011-06-15 アレス トレーディング ソシエテ アノニム 非イオン性界面活性剤を一緒に伴うfsh及びlhの液体医薬組成物
EP1638595B1 (en) * 2003-06-20 2013-03-20 Ares Trading S.A. Freeze-dried fsh / lh formulations
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
WO2006110761A2 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
JP2008535500A (ja) 2005-04-11 2008-09-04 サビエント ファーマセウティカルズ インク. 変異型尿酸オキシダーゼおよびその利用
CN1864744B (zh) * 2005-05-18 2010-09-29 杭州北斗生物技术有限公司 含有尿酸氧化酶的药用制剂
JP2008545665A (ja) * 2005-05-23 2008-12-18 ユニベルシテ ドゥ ジュネーブ 高体温による処置のための注入可能な超常磁性ナノ粒子および高体温インプラントを形成するための使用
EP2013225B1 (en) 2006-04-12 2014-12-17 Crealta Pharmaceuticals LLC Purification of proteins with cationic surfactant
SG176897A1 (en) 2009-06-25 2012-01-30 Savient Pharmaceuticals Inc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
WO2017180594A1 (en) * 2016-04-13 2017-10-19 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
KR101744900B1 (ko) * 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997470A (en) * 1971-10-20 1976-12-14 Mallinckrodt, Inc. Surfactant containing reagent formulations for assaying biological specimens and methods of preparing same
US3928137A (en) * 1971-10-20 1975-12-23 Mallinckrodt Inc Reagent formulation for uric acid assay
JPS51104807A (en) * 1975-03-12 1976-09-17 Hitachi Ltd Teepurekoodano ootoribaasuseigyokairo
JPS5417027A (en) * 1977-07-07 1979-02-08 Canon Inc Image forming system
DE3126759A1 (de) * 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
JPS60224499A (ja) * 1984-04-23 1985-11-08 Toyobo Co Ltd 安定なウリカ−ゼ製剤
DE3743405A1 (de) * 1987-05-14 1988-11-24 Boehringer Mannheim Gmbh Verfahren zur bestimmung von fructosamin
JPH0243471A (ja) * 1988-08-03 1990-02-14 Iwataro Moriyama 立体駐車装置

Also Published As

Publication number Publication date
IL118171A0 (en) 1996-09-12
AU710288B2 (en) 1999-09-16
FR2733914B1 (fr) 1997-08-01
NO315261B1 (no) 2003-08-11
EP0742013A1 (fr) 1996-11-13
ES2137635T3 (es) 1999-12-16
DE69604009T2 (de) 2000-04-06
HUP9601241A3 (en) 2000-06-28
NO961915L (no) 1996-11-12
TW420614B (en) 2001-02-01
AU5213996A (en) 1996-11-21
PL314147A1 (en) 1996-11-12
SG42355A1 (en) 1997-08-15
IL118171A (en) 2000-08-31
CN1090972C (zh) 2002-09-18
ZA963683B (en) 1997-11-10
HU9601241D0 (en) 1996-07-29
BR1100337A (pt) 2000-07-25
DE69604009D1 (de) 1999-10-07
EA199600024A2 (ru) 1996-12-30
HU225147B1 (en) 2006-07-28
CA2175971C (en) 2003-12-30
MX9601756A (es) 1997-07-31
CZ135096A3 (en) 1996-12-11
CA2175971A1 (en) 1996-11-12
NZ286554A (en) 1998-09-24
NO961915D0 (no) 1996-05-10
ATE183925T1 (de) 1999-09-15
EA199600024A3 (ru) 1997-03-31
DK0742013T3 (da) 2000-03-06
CN1147961A (zh) 1997-04-23
SI0742013T1 (en) 1999-12-31
CZ290799B6 (cs) 2002-10-16
US5811096A (en) 1998-09-22
EA000024B1 (ru) 1997-12-30
HUP9601241A2 (en) 1997-04-28
EP0742013B1 (fr) 1999-09-01
PL184135B1 (pl) 2002-09-30
FR2733914A1 (fr) 1996-11-15
JPH0925242A (ja) 1997-01-28
JP2950775B2 (ja) 1999-09-20

Similar Documents

Publication Publication Date Title
ZA963683B (en) Stable liquid composition containing urate oxidase and lyophilized composition for its preparation.
GR3034191T3 (en) Formulations for lipophilic compounds
AU7549696A (en) Bioadhesive pharmaceutical composition for the controlled release of active principles
LU92613I2 (fr) Saxagliptin et ses dérivés pharmaceutiquement acceptables (ONGLYZA)
AU1777495A (en) Stable freeze-dried formulation comprising a protein; assay kit
GR3033204T3 (en) Formulations of blood clot-polymer matrix for delivery of osteogenic proteins.
CA2258095A1 (en) Tetrahydrolipstatin containing compositions
ZA895936B (en) Pharmaceutical compositions comprising selected lactobacillus strains
CA2274485A1 (en) Medicinal composition
EP1013274A3 (en) Composition comprising amoxycillin and clavulanic acid
CA2294448A1 (en) Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins
ITMI911580A1 (it) Preparazioni oftalmiche a rilascio protratto
CA2125643A1 (en) Pharmaceutical composition having analgesic activity
CA2103725A1 (en) Composition for use in transdermal administration
HK1036413A1 (en) Solution comprising prostaglandins and benzyl alcohol.
CA2220103A1 (en) Composition comprising amoxycillin and clavulanic acid
MX9708383A (es) Composicion que comprende amoxicilina y acido clavulanico.
Lambert-Zechovsky et al. Usefulness of time-kill curves to select an optimal beta-lactam-aminoglycoside combination against Pseudomonas aeruginosa. In vitro study of 40 Pseudomonas aeruginosa isolated in pediatric intensive care units.
AU2458492A (en) Medicaments for treating gastrointestinal disorders